Amgen Inc. and AstraZeneca plc's recent five-product inflammation partnership makes them the latest players in the peer-to-peer collaboration game, a business development trend that appears to be gaining traction now that the patent cliff is at hand.
Biotech companies raised $5.15 billion in the first quarter of 2012, about 15 percent less than the $6.07 billion raised in the first quarter last year. Public companies felt the pinch slightly more than private companies: The total amount raised by the former dropped about 16 percent compared to the same period last year, while the total amount raised by the latter dropped about 8 percent.
SAN DIEGO – Despite the imminent arrival of the $1,000 genome, several technical and business hurdles must be overcome to move personalized medicine into the mainstream, according to two recent panels hosted by the San Diego Venture Group and Southern California life sciences industry organization BIOCOM.
I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year. That’s good news, especially given the recent debates about the health of biotech venture and funding for innovation. But it’s interesting to note that if you broaden your view to include not just U.S., but global biotech fundraising, and not just venture-backed deals but all non-partnering money raised by private companies – you see that the $774 million raised in Q1 2012 represents a slight...
When Warp Drive Bio LLC emerged on the biotech scene earlier this year, the start-up's unique business model, jointly backed by Third Rock Ventures LLC and Sanofi SA, garnered plenty of buzz. But equally innovative, if not equally attention-getting, is the Cambridge, Mass.-based biotech's take on drug discovery.
Biotech companies raised $5.15 billion in the first quarter of 2012, about 15 percent less than the $6.07 billion raised in the first quarter last year. Public companies felt the pinch slightly more than private companies: The total amount raised by the former dropped about 16 percent compared to the same period last year, while the total amount raised by the latter dropped about 8 percent.
Are you looking for a venture capitalist to lead your next financing round, take a seat on your board and add hands-on value to your biotech? Then Correlation Ventures is not for you. But if you've got enough of those types of investors already – maybe more than you'd like – and you just want a little money to fill out your round, give Correlation a call.
In the first two parts of BioWorld Insight's Innovation Analysis, we explored how although the creation and funding of new biotechs is not necessarily synonymous with the creation and funding of innovation, there are signs that venture capitalists are more willing to invest in innovative, early stage biotechs than they were five or six years ago.
The first part of BioWorld Insight's Innovation Analysis showed that while biotech Series A funding jumped 39 percent between 2010 and 2011, the percentage of that money allocated to so-called specialty pharma firms jumped 45 percent.
Oncothyreon Inc. raised $47 million through a public offering of 11.75 million shares priced at $4 apiece. The price represents an 8 percent discount to Wednesday's closing price of $4.35, and shares of Seattle-based Oncothyreon (NASDAQ:ONTY) dipped 10 cents to close at $4.25 on Thursday.
